This led to our development and prospective validation of our revised and improved IGF/CTP scoring system, which replaced the subjective clinical assessment of ascites and encephalopathy included in the original CTP scoring system with objectively quantified plasma IGF-1 levels and created new IGF/CTP score classes (A-C). The gene discussed is IGF1; the disease is Encephalopathy.